Summa Equity acquires Axion BioSystems, to accelerate understanding of cell behaviour in drug discovery and development
Summa Equity Fund II has acquired Axion BioSystems, a US life science tools business specializing in the development, production, and marketing of MEA (Microelectrode Arrays) and impedance technologies. Its tools are used to understand cell behavior and function in real-time, for applications including cell and gene therapy (CGT)16 July 2021, Stockholm, Sweden: Summa Equity Fund II (“Summa”) has acquired a majority stake in Axion BioSystems , a leading provider of MEA and impedance technology for single-cell analysis. Axion